About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist chemotherapy and identify better ways to treat those cancers, researchers at Baylor College of Medicine have conducted a detailed molecular analysis of MIBC tumors. The results, published in Cell Reports Medicine, offer potential new ways to identify which patients will benefit from chemotherapy and reveal possible new treatment strategies.
This article was originally published on MedicalXpress.com
